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through a transarterial route.1,3-5 This procedure is per-
formed with the cannulating and traversing of collateral
networks and the selective embolization of the responsible
feeding artery before it enters the aneurysm sac. Recently,
the technique of translumbar endoleak embolization has
been described.6 With this technique, the endoleak is
entered directly and the coil is embolized. Although indi-
vidual vessels that are responsible for endoleak ingress and
egress (IMAs and lumbar arteries) are not embolized, the
communication between them is eliminated. The purpose
of our investigation was the evaluation and comparison of
the efficacy of translumbar and transarterial embolization
procedures in patients in whom type 2 endoleaks develop
after endovascular aneurysm repair.
METHODS
An Institutional Review Board exemption by the
office of regulatory affairs was granted for this retrospec-
tive review. The medical records of the patients who
underwent endovascular aneurysm repair were reviewed
for the presence or absence of endoleaks and for the
response to various endoleak treatment procedures.
The patients with endoleaks that were identified with
30-day postoperative CT scanning underwent diagnostic
angiography for the proper classification of the leaks. This
Endoleaks occur with a variety of mechanisms, but the
most frequent is from retrograde aortic branch flow into
the aneurysm sac (type 2 aneurysm). Approximately 20%
of the patients who have undergone endovascular
aneurysm repair will have this type of leak develop.1 At
this point in time, the consequences of type 2 endoleaks
are unknown. Because of this uncertainty, some physicians
choose to follow patients with serial imaging and to inter-
vene only when there is aneurysm enlargement.2 Other
physicians repair collateral endoleaks as soon as they are
shown on follow-up computed tomographic (CT) scan
results.1 Treatment typically involves transarterial
embolization of the dominant feeding artery (either the
inferior mesenteric artery [IMA] or the lumbar artery)
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Objective: The exact significance of collateral endoleaks is unknown and a topic of great debate. Because of this uncer-
tainty, some physicians choose to watch and wait while others aggressively treat these leaks. The purpose of this inves-
tigation was the evaluation of the efficacy of the two techniques used in the treatment of collateral endoleaks that occur
after endovascular aneurysm repair.
Methods: Patients with 33 angiographically proven type 2 endoleaks underwent treatment with either transarterial infe-
rior mesenteric artery embolization (n = 20) or direct translumbar embolization (n = 13) during an 18-month period.
Embolization success was defined as resolution of endoleak on all subsequent computed tomography angiogram results.
The likelihood of embolization failure between the two treatments was expressed as a risk ratio and was compared with
Fisher exact test.
Results: Sixteen of 20 transarterial inferior mesenteric artery embolizations (80%) failed with recanalization of the orig-
inal endoleak cavity over time. A single failure (8%) in the direct translumbar embolization group occurred in a patient
in whom a new attachment site leak developed. The remaining 12 translumbar endoleak embolizations (92%) were suc-
cessful and durable, with a median follow-up period of 254 days. The patients who underwent transarterial inferior
mesenteric artery embolization were significantly more likely to have persistent endoleak than were the patients who
underwent treatment with direct translumbar embolization (risk ratio, 4.6; 95% confidence interval, 1.9 to 11.2; P =
.0001).
Conclusion: The transarterial embolization of inferior mesenteric arteries for the repair of type 2 endoleaks is ineffec-
tive and should not be performed. Direct translumbar embolization of the endoleak is effective in the elimination of
type 2 leaks and should be the therapy of choice when aggressive endoleak management is indicated. (J Vasc Surg
2002;35:23-9.)
procedure was performed through a transfemoral
approach with either a 5F or 5.5F catheter. All the
endoleak angiograms were performed in a standardized
fashion. First, anterior-posterior and lateral pigtail aortog-
raphy was performed at the proximal attachment site with
nonionic iodinated contrast (Omnipaque 300, Nycomed
Inc, Princeton, NJ), a power injector, and high flow rates
(20 to 30 mL/s for 2 to 4 seconds). The pigtail catheter
then was pulled into the stent graft and positioned above
the flow divider where bilateral oblique views were
obtained. During this portion of the procedure, care was
taken not to use injection rates that would reflux contrast
up to the proximal attachment site. The rates in this phase
of the examination ranged from 5 to 10 mL/s for 3 to 5
seconds. The pigtail catheter then was exchanged for
either a 5.5F Simon’s 1 catheter (Cook Inc, Bloomington,
Ind) or a 5F Cobra catheter (Boston Scientific Corp,
Watertown, Mass), and selective angiography of the supe-
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Fig 1. Inferior mesenteric artery (IMA) embolization failure. A, Brisk retrograde flow through IMA and into aneurysm sac results in
large type 2 endoleak (arrows) in patient with bifurcated Talent graft (Medtronics Corporation, Minneapolis, Minn). Endoleak angiog-
raphy was performed through microcatheter positioned in distal IMA. Coil embolization of proximal IMA was then performed until sta-
sis. Endoleak was resolved on computed tomographic scan results 30 days after embolization. B, Computed tomographic scan results 6
months after embolization show recanalization of endoleak (arrows; C, embolization coils). C, IMA remains occluded on repeat
endoleak angiographic scan results, which suggests additional vessels have been recruited as endoleak inflow.
A
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rior mesenteric and internal iliac arteries was performed.
Filming for all the injections was at three frames per sec-
ond and was carried through the venous phase to allow for
delayed retrograde collateral filling of the endoleak.
Once a patient was confirmed to have a type 2
endoleak (on endoleak angiographic results), the patient
underwent treatment with either transarterial IMA or
translumbar embolization. This usually was performed at
a separate sitting. Because our endoleak treatment algo-
rithm evolved over time, the treatment an individual
patient underwent depended on when in our series the
endoleak was identified. Early in our experience, the
patients with type 2 endoleaks underwent transarterial
embolization of the aortic branch vessels through the
superior mesenteric and lumbar arteries. In this initial
stage, translumbar embolization was reserved for the
patients in whom there was either a procedural or treat-
ment failure. Later in our series, we used translumbar
endoleak embolization as our primary endoleak treatment
method.
Transarterial embolization. We have previously
reported our transarterial embolization technique.1
Briefly, a 3F 180-cm microcatheter (Fast Tracker 18,
Boston Scientific, Natick, Mass) was advanced through
the superior mesenteric artery and the middle colic arter-
ies and then was advanced to the proximal portion of the
IMA where microcoils were deployed until radiographic
evidence of stasis of blood flow was obtained.
Translumbar embolization. We also have previously
described our translumbar endoleak embolization tech-
nique.6 The patients underwent treatment in a prone posi-
tion with fluoroscopic guidance. The endoleaks were
identified on prior CT scans and referenced to fluoro-
scopic landmarks. The localization of the endoleak to spe-
cific radiopaque markers on the stent graft itself also was
helpful. A 19-gauge 20-cm needle with a 5F Teflon sheath
(Boston Scientific Corp) was inserted through the back at
the level of the endoleak approximately 4 to 5 fingers’
breadth from the midline at a 45-degree angle. We aimed
for the vertebral body to avoid the transverse processes.
Once the needle rested on the vertebral body, it was with-
drawn several centimeters and redirected slightly anteri-
orly. This anterior redirection continued until the needle
was free of the vertebrale body and the aneurysm sac was
punctured. The entrance to the sac was indicated with a
slow ooze of blood through the needle. The
needle/sheath system then was positioned directly within
the endoleak, which was signaled with brisk and pulsatile
blood return. We found it useful to alternate frequently
between the anterior-posterior and lateral projections as
the needle was advanced through the sac into the endoleak
cavity. This process allowed for the precise positioning of
the needle/sheath system within the endoleak and
decreased the possibility of endograft puncture. Endoleak
angiography, pressure measurements, and coil emboliza-
tion of the endoleak cavity then were performed.
Embolization was achieved with the formation of a nest of
12-mm, 10-mm, and 8-mm Gianturco coils (Cook, Inc)
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directly within the endoleak cavity. The feeding IMA and
lumbar arteries were not selectively catheterized from
within the endoleak. Instead, the direct communication of
these vessels (the endoleak itself) was disrupted by the
embolization. We first soaked the coils in a thrombin solu-
tion that contained 20,000 units of thrombin (Gentrac
Inc, Middleton, Wis) in 20 milliliters of saline solution
before deployment to hasten clotting. Embolization con-
tinued until there was no further blood return and there
was an associated sac pressure drop to approximately 20
mm Hg. The patients underwent follow-up postemboliza-
tion CT scanning at 30 days, at 6 months, and then annu-
ally. The CT scans were obtained dynamically and were
delayed with a spiral acquisition with 3-mm slice thickness.
Embolization success was defined as resolution of
endoleak on all subsequent CT angiographic scan results.
Any endoleak that was identified on postembolization CT
angiographic scan was defined as a failure. The likelihood
of embolization failure between the two treatments was
expressed as a risk ratio and was compared with Fisher
exact test.
RESULTS
Thirty-three angiographically proven type 2 endoleaks
in 19 patients were treated with either transarterial IMA (n
= 20) or direct translumbar (n = 13) embolizations. These
procedures were performed on 21 patients with Talent
stent grafts (Medtronics Corporation, Minneapolis,
Minn), on eight patients with Ancure stent grafts
(Guidant Corporation, Indianapolis, Ind), and on four
patients with AneuRx stent grafts (Medtronics
Corporation). Seventeen patients had treatment results
that were failures. These patients had additional endoleaks
develop after primary endoleak repair.
Transarterial inferior mesenteric artery emboliza-
tion. Sixteen of twenty transarterial IMA embolizations
(80%) failed with the recanalization of the original
endoleaks over time (Table). Of these, 13 patients had res-
olution of the endoleak on the initial 30-day postem-
bolization CT scan results but recanalization on
subsequent imaging results (Fig 1). One patient had initial
negative postembolization CT scan results but has refused
additional imaging since then. The mean follow-up period
in the three patients with successful treatments (with fol-
low-up examination) was 396 days. In addition, there
were two procedural failures in patients with incomplete
Endoleak embolization treatment results: method and
results of type 2 embolization techniques are shown
Type of embolization
IMA TLA
Success 4 12
Failure 16 1
IMA, Inferior mesenteric artery; TLA, translumbar.
Riolan’s arches that did not allow for retrograde IMA
catheterization. There were no procedural-related compli-
cations.
Translumbar embolization. All the translumbar
endoleak procedures were successful (Fig 2). The
endoleak channel was entered in all the patients, and direct
endoleak angiography was performed. No endografts were
perforated with this technique. Twelve of 13 patients
(92%) had a durable result, with a median follow-up
period of 254 days. All the procedures were completed in
less than an hour, and there were no procedural-related
complications. A single failure in the group occurred in a
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Fig 2. Inferior mesenteric artery (IMA) embolization failure followed by successful translumbar endoleak embolization. A, Transarterial
endoleak angiography performed through microcatheter (arrow) positioned in IMA in this patient with bifurcated Talent graft
(Medtronics Corporation, Minneapolis, Minn). Retrograde IMA flow and filling of large collateral endoleak (E) is shown. Dominant
lumbar artery (L) is seen draining endoleak with faint opacification of second lumbar artery (*). IMA was embolized to stasis. B,
Computed tomographic scan results 4 months after IMA embolization (arrow) show recanalization of endoleak (E). C, Direct translum-
bar angiography then was performed, and results showed continued coil occlusion of IMA (I). Endoleak, however, had changed shape
and had recruited an additional lumbar artery (L). This vessel in retrospect was seen on initial arterial study (A) before IMA emboliza-
tion (*). Endoleak then was coil embolized. D, Computed tomography angiographic scan results 6 months after translumbar artery
embolization show complete resolution of endoleak with shrinkage of aneurysm sac. Coils are seen in region of prior endoleak and IMA.
A B
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patient who had a new attachment site leak develop. This
patient had undergone successful translumbar emboliza-
tion with endoleak-free CT scan results at 6 months. Eight
months after embolization, the patient suddenly felt a pul-
satile mass in her abdomen. CT scan and angiographic
results obtained at that time showed a proximal attach-
ment site failure with migration of the stent graft into the
aneurysm sac.
Nine patients with unsuccessful transarterial IMA
embolizations went on to translumbar procedures, at which
time direct endoleak angiography was performed. In every
patient, there was continued occlusion of the IMA (from
the prior procedure) with recruitment of additional lumbar
arteries feeding or draining into the endoleak (Fig 1).
Comparison of transarterial and translumbar endo-
leak embolization techniques. The patients who under-
went transarterial IMA embolization were significantly
more likely to have recurrent endoleak than were the
patients who underwent treatment with direct translumbar
embolization (risk ratio, 4.6; 95% confidence interval, 1.9
to 11.2; P = .0001).
DISCUSSION
Systemic pressure recently has been revealed within the
aneurysm sacs of patients with collateral endoleaks.7 This
discovery would suggest that these patients remain unpro-
tected and at risk for aneurysm rupture. Because of this risk,
some centers aggressively treat these types of leak.1 Other
physicians wait for the endoleaks to spontaneously throm-
bose and intervene only if there is continued aneurysm
expansion.8-10 As the debate concerning the time of treat-
ment for these patients continues, little attention has been
given to the determination of the best treatment.
Several collateral endoleak treatment strategies have
been proposed.2,8,11-13 Two years ago, we reported our
first experience with transarterial embolization of collat-
eral endoleaks.1 Eight patients underwent successful treat-
ment with IMA embolization. No residual endoleaks were
seen on the 30-day postembolization CT scan results, and
we believed that these patients were cured. Unfortunately,
seven of these eight patients had their collateral endoleaks
recanalize over time. Repeat endoleak angiographic results
showed continued thrombosis of the IMA but recruit-
ment of additional arterial feeders. It became clear to us
that type 2 endoleaks were behaving like arterial malfor-
mations and that single vessel arterial embolization was
ineffective.
That arterial malformations cannot be successfully
treated unless the central nidus is eliminated is well estab-
lished.14,15 The embolization of a single feeding artery is
ineffective because additional flow is recruited from
nearby vessels. We believe this is also the case with
endoleaks and is the reason for our embolization failures.
If, for example, the inflow of a collateral endoleak was
from the IMA and outflow through several lumbar arter-
ies, the embolization of the IMA inflow would only
enlarge and change the flow in neighboring vessels (lum-
bar arteries) and the leak would recur (Fig 2). We cannot
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explain the experience of one center that reported suc-
cessful IMA embolization in 11 patients with a 2-year fol-
low-up period.3
Translumbar embolization occludes the endoleak
itself, which prevents abnormal communication between
the aortic branch vessels in the aneurysm sac. This is anal-
ogous to central nidus embolization in arteriovenous mal-
formations. We believe this is the reason for its increased
durability over transarterial techniques.
The exact mechanism of type 2 endoleak formation is
unknown. After endovascular aneurysm repair, many
potential communications exist between aortic branch ves-
sels (IMA, lumbar arteries, etc) through the aneurysm sac.
It is when these connections fail to thrombose and propa-
gate that type 2 endoleaks develop. Flow into and out of
the leak can be variable and can change depending on the
path of least resistance. We saw this process in our study in
the nine patients who underwent unsuccessful IMA
embolization followed by translumbar embolization.
These patients underwent endoleak angiography both
before and after IMA occlusion. In each patient, we saw
redistribution of flow through lumbar arteries as a
response to transarterial IMA embolization, which
explains the recanalization that occurred.
Some type 2 endoleaks have been shown to throm-
bose if left alone while others will develop in patients with
prior negative CT scan results.8,10 From our work, it is
clear that the formation of collateral endoleaks represents
an extremely dynamic process. Our observation that pre-
viously occluded aortic branch vessels can be recanalized
(or more likely were never thrombosed in the first place)
and can contribute to late endoleak formation and remod-
eling was surprising.
Some investigators have proposed either open surgical
or laparoscopic ligation of IMA and lumbar arteries as a
way to treat branch endoleaks.13 We believe that for these
techniques to produce a durable result every aortic branch
must be ligated or additional collateral vessels will be
recruited by the endoleak. We have shown that the key to
durable endoleak repair is the destruction of the commu-
nication between the aortic branch vessels (the endoleak
cavity). Ligation of these vessels individually with laparo-
scopic techniques should be no more effective than our
transarterial embolization procedures.
We believe that the key to type 2 endoleak repair is the
prevention of the development of these leaks in the first
place. Walker, Macierewicz, and Hopkinson16 and others
have injected thrombogenic material into the aneurysm
sacs of patients at the time of endovascular aneurysm repair
to promote sac thrombosis and thereby prevent the devel-
opment of collateral leaks.17 We believe that this is the cor-
rect endoleak treatment approach to take. Any material
that will enhance thrombosis or sever communication
between aortic branch vessels within the aneurysm sac
should decrease collateral endoleak formation. We also
expect materials to be developed in the near future that will
not only promote sac thrombosis but also provide struc-
tural support for the graft.
Our findings have led to a change in the management
of patients with type 2 endoleaks at our hospital. Once an
endoleak is identified on CT scanning results, the patients
undergo contrast angiography for the identification of the
source of the leak. We think that this step is necessary
because the cause of endoleaks cannot be reliably ascer-
tained from CT angiographic results alone. We believe
that the translumbar embolization of type 1 or type 3
endoleaks would be ineffective and would delay definitive
treatment. Only when a type 2 endoleak is confirmed on
angiographic results does the patient undergo translumbar
endoleak embolization (Fig 3). In light of our current
findings, we believe that there is little role for transarterial
endoleak embolization.
In summary, we have shown that collateral endoleaks
are complex vascular structures with numerous flow chan-
nels and potential feeders. After transarterial IMA
embolization, flow is redistributed as ingress changes,
which eventually recanalizes the leak. Although longer fol-
low-up examination is still needed, we have shown that
direct translumbar endoleak embolization provides a more
durable result and should be the treatment of choice when
aggressive endoleak management is indicated.
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lumbar was not embolized because this would not have provided long-term thrombosis of endoleak. B, Patient was returned for
translumbar endoleak embolization to thrombose endoleak cavity. Direct endoleak angiographic scan results show endoleak (E) in
greater detail. Not only is the same lumbar artery identified that was seen on transarterial study (arrow), but many additional vessels are
identified that contribute to endoleak. Endoleak nidus then was coil embolized.
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Dr Julie Ann Freischlag (Los Angeles, Calif). Patients in this
study were chosen based on a 30-day postoperative CT scan. Was
that the only criterion? Did the authors evaluate the size of the
aneurysm or any other criteria to determine whether or not you
should proceed to further delineate the endoleak?
As you know, last month a multicenter study was approved by
CSEC to do a prospective, randomized trial of open versus
endovascular repair of aneurysms, and we’re going to do this in
40 VA Medical Centers. What criteria should we use to treat
endoleaks, since that’s going to be utilized as one of the sec-
ondary endpoints? And what method should we use? What is the
role of aneurysm sac pressure measurements, as you certainly are
one of the people that know most about that? And does it make
any difference what kind of graft is in there as far as how aggres-
sive we should be with the endoleak treatment?
Dr Richard A. Baum. We understand a lot more about
endoleaks now than we ever have. It is important to keep things
in perspective. Type 2 endoleaks are a potential complication in a
procedure we don’t even know its long-term results in. Ten years
from now we can look back and determine outcomes in patients
with and without endoleaks, and compare the two groups. Right
now we don’t have the liberty to do that. So we don’t know the
exact significance of endoleaks.
On the other hand, there are things we do about endoleaks.
We know that they have pressure in them. We know that this pres-
sure is transmitted across the aneurysm thrombus to the
aneurysm wall. We know that patients who have endoleaks that
either thrombose spontaneously or are treated do significantly
better in terms of aneurysm shrinking than patients who have
untreated endoleaks.
I think there are certain absolute indications for endoleak
treatment. Do not tolerate an aneurysm that is expanding in size
if there is an endoleak. With these techniques these patients can
be treated and you’ll have shrinkage.
Other than that, when to intervene? We intervene really at 6
months. We get a CT scan at 30 days. If that CT scan has an
endoleak, we do an arteriogram just to make sure it’s not a type
1 or a type 3 endoleak. And then we’ll wait. We’ll wait 6 months
to see whether it will thrombose on its own. If it thromboses,
fine. If not, then we’ll bring the patient back for a translumbar
arteriogram and embolization.
Dr David C. Brewster (Boston, Mass). Dr Baum, we share
your enthusiasm, when indicated, for a direct translumbar
approach. But to reemphasize points made by previous discussants,
I think we urge conservatism about treating endoleaks. Endoleaks
are a complex topic, and I think the relationship between an
observed leak and outcome parameters that are really significant to
the patient remains quite uncertain. So we intervene for type 2
branch leaks only if there’s documented aneurysm expansion.
My main questions relate to what material to embolize into
the sac. I believe you use metal coils. We pretty much do the
same. But the trouble is that such materials confound later CT
scans in terms of follow-up and the ability to determine whether
the endoleak is obliterated. So what are your thoughts about
other materials? We have tried thrombin but had some adverse
problems with that. In fact, one patient ended up with a neuro-
logic incident in the lower extremity because of presumed plex-
opathy secondary to direct intrasac injection of thrombin.
And finally, in those patients that you have treated, do you
have positive outcome data such as shrinkage of aneurysm sac
maximal diameter or diminished sac volume measurements that
document that direct sac embolization is beneficial?
Dr Baum. The last part will obviously be a future publication.
Hopefully at next year’s meeting we’ll be able to present that data.
In terms of your first point, I agree with you. I don’t think
we know what endoleaks do long term. We tend to err on the
more conservative side. The procedure is a very quick procedure,
has very little morbidity. And I think that just intuitively, if you
have an endoleak, you know there’s pressure in that endoleak,
why not fix it if you can?
In terms of what we use for embolic material, we use coils.
We’ve started now using a liquid embolic agent, a glue. The
problem with coils is you have to use a lot of coils. Glue mate-
rial, where you can just seal the inside, won’t have problems
with the imaging, and you can make it any consistency you
want, almost like a foam, and make it go out into the branch
vessels only several centimeters. I wouldn’t use thrombin
because it goes out too far. I would also stay away from parti-
cles. In the next year we’ll use coils, and we’ll use coils and
glue. And I think when we get more comfortable with the glue,
we’ll just use glue alone.
Dr Christopher K. Zarins (Stanford, Calif). You have taken
a very aggressive approach to type 2 endoleaks, whereas others
have taken a more moderate approach in observing type 2
endoleaks. I wonder if you could share with us your data on the
primary endpoints of aneurysm repair, namely, rupture rate, sur-
gical conversion rate, and aneurysm enlargement rate, and, most
importantly, prevention of aneurysm-related death, which is
death from a primary procedure plus the death rates from sec-
ondary procedures. Because these are the endpoints that I think
are going to be the most important in evaluating the effective-
ness of the therapy.
Dr Baum. That brings up what I said with the first question.
That we don’t know. And at our center, since we treat all of the
patients with endoleaks, we can’t randomize them into treatment
and nontreatment groups. I guess what we could do is compare
our experience with other sites who watch endoleaks.
I think the important point about this paper here is telling
people how to intervene. You can intervene whenever you want.
What we’re presenting here today is that if you do intervene with
a patient with a type 2 endoleak, don’t do a transarterial emboliza-
tion, it’s not going to work. That was what we presented today.
DISCUSSION
